Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 212

Similar articles for PubMed (Select 23066316)

1.

Effectiveness of infliximab after adalimumab failure in Crohn's disease.

Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP.

World J Gastroenterol. 2012 Oct 7;18(37):5219-24. doi: 10.3748/wjg.v18.i37.5219.

2.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
3.

Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.

Da W, Zhu J, Wang L, Lu Y.

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):885-91. doi: 10.1097/MEG.0b013e32836220ab. Review.

PMID:
23817447
4.

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P.

Gut. 2012 Feb;61(2):229-34. doi: 10.1136/gutjnl-2011-300755. Epub 2011 Sep 23.

PMID:
21948942
5.

[Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Kiss T, Wittmann T.

Orv Hetil. 2011 Jun 12;152(24):951-7. doi: 10.1556/OH.2011.29128. Hungarian.

PMID:
21609921
6.

Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T.

J Gastrointestin Liver Dis. 2012 Sep;21(3):265-9.

7.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

8.

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.

Sprakes MB, Hamlin PJ, Warren L, Greer D, Ford AC.

J Crohns Colitis. 2011 Aug;5(4):324-31. doi: 10.1016/j.crohns.2011.02.007. Epub 2011 Mar 10.

PMID:
21683302
9.

Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.

Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Álvarez A, Romero Vázquez J, Herrerías Gutiérrez JM.

Rev Esp Enferm Dig. 2011 Jun;103(6):294-8.

10.

Elective switching from infliximab to adalimumab in stable Crohn's disease.

Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6. doi: 10.1097/MIB.0b013e3182802ae1.

PMID:
23446337
11.

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Bigard MA.

Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.

12.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22.

PMID:
22519466
13.

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.

Billioud V, Sandborn WJ, Peyrin-Biroulet L.

Am J Gastroenterol. 2011 Apr;106(4):674-84. doi: 10.1038/ajg.2011.60. Epub 2011 Mar 15. Review.

PMID:
21407178
14.

Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.

Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.

Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar;114(1):85-90.

PMID:
20509281
15.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.

PMID:
17470824
16.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.

Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71.

PMID:
19465858
17.

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.

Eur J Gastroenterol Hepatol. 2010 Mar;22(3):334-9. doi: 10.1097/MEG.0b013e32832b20d4.

PMID:
19528808
18.

Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.

Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.

Aliment Pharmacol Ther. 2007 Apr 1;25(7):787-96.

19.

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28.

PMID:
20955442
20.

[Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].

Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.

Przegl Lek. 2011;68(9):602-5. Polish.

PMID:
22335009
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk